Construction of an Immune-related LncRNA Signature Pair for Predicting Oncologic Outcomes and the Sensitivity of Immunosuppressor in Treatment of Lung Adenocarcinoma

Overview

Journal Respir Res

Specialty Pulmonary Medicine

Date 2022 May 13

PMID 35562727

Authors

Jinman Zhuang

Zhongwu Chen

Zishan Chen

Jin Chen

Maolin Liu

Xinying Xu

Yuhang Liu

Shuyan Yang

Zhijian Hu

Fei He

Affiliations

Soon will be listed here.

Abstract

Background: Although immunotherapy has shown clinical activity in lung adenocarcinoma (LUAD), LUAD prognosis has been a perplexing problem. We aimed to construct an immune-related lncRNA pairs (IRLPs) score for LUAD and identify what immunosuppressor are appropriate for which group of people with LUAD.

Methods: Based on The Cancer Genome Atlas (TCGA)-LUAD cohort, IRLPs were identified to construct an IRLPs scoring system by Cox regression and validated in the Gene Expression Omnibus (GEO) dataset using log-rank test and the receiver operating characteristic curve (ROC). Next, we used spearman's correlation analysis, t-test, signaling pathways analysis and gene mutation analysis to explore immune and molecular characteristics in different IRLP subgroups. The "pRRophetic" package was used to predict the sensitivity of immunosuppressant.

Results: The IRLPs score was constructed based on eight IRLPs calculated as 2.12 × (MIR31HG|RRN3P2) + 0.43 × (NKX2-1-AS1|AC083949.1) + 1.79 × (TMPO-AS1|LPP-AS2) + 1.60 × (TMPO-AS1|MGC32805) + 1.79 × (TMPO-AS1|PINK1-AS) + 0.65 × (SH3BP5-AS1|LINC01137) + 0.51 × (LINC01004|SH3PXD2A-AS1) + 0.62 × (LINC00339|AGAP2-AS1). Patients with a lower IRLPs risk score had a better overall survival (OS) (Log-rank test P < 0.001, P = 0.017, P = 0.027) and similar results were observed in the AUCs of TCGA dataset and GEO dataset (AUC = 0.777, AUC = 0.685, AUC = 0.733, AUC = 0.680). Immune score (Cor = -0.18893, P < 0.001), stoma score (Cor = -0.24804, P < 0.001), and microenvironment score (Cor = -0.22338, P < 0.001) were significantly decreased in the patients with the higher IRLP risk score. The gene set enrichment analysis found that high-risk group enriched in molecular changes in DNA and chromosomes signaling pathways, and in this group the tumor mutation burden (TMB) was higher than in the low-risk group (P = 0.0015). Immunosuppressor methotrexate sensitivity was higher in the high-risk group (P = 0.0052), whereas parthenolide (P < 0.001) and rapamycin (P = 0.013) sensitivity were lower in the high-risk group.

Conclusions: Our study established an IRLPs scoring system as a biomarker to help in the prognosis, the identification of molecular and immune characteristics, and the patient-tailored selection of the most suitable immunosuppressor for LUAD therapy.

Citing Articles

Long Non-Coding RNA : A Comprehensive Overview on Its Biological Functions and Clinical Significances in Human Cancers.

Ma F, Zhang B, Wang Y, Lou C Molecules. 2024; 29(15).

PMID: 39124865 PMC: 11314102. DOI: 10.3390/molecules29153461.

LncRNAs in Immune and Stromal Cells Remodel Phenotype of Cancer Cell and Tumor Microenvironment.

Li W, Zhang H, You Z, Guo B J Inflamm Res. 2024; 17:3173-3185.

PMID: 38774447 PMC: 11108079. DOI: 10.2147/JIR.S460730.

LncRNA SH3BP5-AS1 promotes hepatocellular carcinoma progression by sponging miR-6838-5p and activation of PTPN4.

Zhao X, Zhu X, Xiao C, Hu Z Aging (Albany NY). 2024; 16(10):8511-8523.

PMID: 38761175 PMC: 11164516. DOI: 10.18632/aging.205811.

Integrative learning in developing an immunologic lncRNA signature as a consensus risk-stratification tool for lung adenocarcinoma.

Chen Z, Liu Y, Wan C, Huang W J Thorac Dis. 2023; 15(4):1823-1837.

PMID: 37197549 PMC: 10183502. DOI: 10.21037/jtd-23-372.

Comprehensive analyses of molecular features, prognostic values, and regulatory functionalities of mA-modified long non-coding RNAs in lung adenocarcinoma.

Ping Y, Huang J, Zhu J, Sun Z, Shang A, Chen C Clin Epigenetics. 2023; 15(1):60.

PMID: 37029420 PMC: 10082542. DOI: 10.1186/s13148-023-01475-z.

References

Chae Y, Davis A, Agte S, Pan A, Simon N, Iams W . Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer. Oncologist. 2019; 24(6):820-828. PMC: 6656496. DOI: 10.1634/theoncologist.2018-0433. View

Cappelli L, Gutierrez A, Baer A, Albayda J, Manno R, Haque U . Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis. 2016; 76(1):43-50. PMC: 5333990. DOI: 10.1136/annrheumdis-2016-209595. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Halbert B, Einstein D . Hot or Not: Tumor Mutational Burden (TMB) as a Biomarker of Immunotherapy Response in Genitourinary Cancers. Urology. 2020; 147:119-126. DOI: 10.1016/j.urology.2020.10.030. View

Garon E, Hellmann M, Rizvi N, Carcereny E, Leighl N, Ahn M . Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. J Clin Oncol. 2019; 37(28):2518-2527. PMC: 6768611. DOI: 10.1200/JCO.19.00934. View

Park J, Kang Y, Hwang S, Oh S, Byun J . Parthenolide Has Negative Effects on In Vitro Enhanced Osteogenic Phenotypes by Inflammatory Cytokine TNF-α via Inhibiting JNK Signaling. Int J Mol Sci. 2020; 21(15). PMC: 7432707. DOI: 10.3390/ijms21155433. View

Chen J, Yang H, Teo A, Amer L, Sherbaf F, Tan C . Genomic landscape of lung adenocarcinoma in East Asians. Nat Genet. 2020; 52(2):177-186. DOI: 10.1038/s41588-019-0569-6. View

Liu Y, Liu Z, Zeng X, Bai C, Chen L, Lin S . Fatal myositis and spontaneous haematoma induced by combined immune checkpoint inhibitor treatment in a patient with pancreatic adenocarcinoma. BMC Cancer. 2019; 19(1):1193. PMC: 6896742. DOI: 10.1186/s12885-019-6372-z. View

Kuswanto W, MacFarlane L, Gedmintas L, Mulloy A, Choueiri T, Bermas B . Rheumatologic symptoms in oncologic patients on PD-1 inhibitors. Semin Arthritis Rheum. 2017; 47(6):907-910. DOI: 10.1016/j.semarthrit.2017.10.018. View

10.

Cheng X, Yin H, Fu J, Chen C, An J, Guan J . Aggregate analysis based on TCGA: TTN missense mutation correlates with favorable prognosis in lung squamous cell carcinoma. J Cancer Res Clin Oncol. 2019; 145(4):1027-1035. DOI: 10.1007/s00432-019-02861-y. View

11.

Mostafa A, Morris D . Immunotherapy for Lung Cancer: Has it Finally Arrived?. Front Oncol. 2014; 4:288. PMC: 4206190. DOI: 10.3389/fonc.2014.00288. View

12.

Mony J, Schuchert M . Prognostic Implications of Heterogeneity in Intra-tumoral Immune Composition for Recurrence in Early Stage Lung Cancer. Front Immunol. 2018; 9:2298. PMC: 6196259. DOI: 10.3389/fimmu.2018.02298. View

13.

Atianand M, Caffrey D, Fitzgerald K . Immunobiology of Long Noncoding RNAs. Annu Rev Immunol. 2017; 35:177-198. PMC: 6449690. DOI: 10.1146/annurev-immunol-041015-055459. View

14.

Kostine M, Rouxel L, Barnetche T, Veillon R, Martin F, Dutriaux C . Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study. Ann Rheum Dis. 2017; 77(3):393-398. DOI: 10.1136/annrheumdis-2017-212257. View

15.

Karam L, Abou Staiteieh S, Chaaban R, Hayar B, Ismail B, Neipel F . Anticancer activities of parthenolide in primary effusion lymphoma preclinical models. Mol Carcinog. 2021; 60(8):567-581. DOI: 10.1002/mc.23324. View

16.

Melissaropoulos K, Klavdianou K, Filippopoulou A, Kalofonou F, Kalofonos H, Daoussis D . Rheumatic Manifestations in Patients Treated with Immune Checkpoint Inhibitors. Int J Mol Sci. 2020; 21(9). PMC: 7247001. DOI: 10.3390/ijms21093389. View

17.

Niu H, Wang J, Li H, He P . Rapamycin potentiates cytotoxicity by docetaxel possibly through downregulation of Survivin in lung cancer cells. J Exp Clin Cancer Res. 2011; 30:28. PMC: 3065416. DOI: 10.1186/1756-9966-30-28. View

18.

Li X, Huang R, Li M, Zhu Z, Chen Z, Cui L . Parthenolide inhibits the growth of non-small cell lung cancer by targeting epidermal growth factor receptor. Cancer Cell Int. 2020; 20(1):561. PMC: 7686780. DOI: 10.1186/s12935-020-01658-1. View

19.

Romano S, Di Pace A, Sorrentino A, Bisogni R, Sivero L, Romano M . FK506 binding proteins as targets in anticancer therapy. Anticancer Agents Med Chem. 2010; 10(9):651-6. DOI: 10.2174/187152010794479816. View

20.

Cappelli L, Brahmer J, Forde P, Le D, Lipson E, Naidoo J . Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen. Semin Arthritis Rheum. 2018; 48(3):553-557. PMC: 6150859. DOI: 10.1016/j.semarthrit.2018.02.011. View